Product Pipeline

VBS is prioritizing its research and development efforts in areas where we can make a meaningful contribution to patients with significant unmet medical needs. Through major research efforts across multiple product lines — including targeted pharmaceuticals, interventional devices and molecular diagnostics — VBS is developing targeted solutions for serious diseases. We are dedicated to delivering innovative biomedical technologies that will benefit patients in need around the world.

In May 2015, Vascular BioSciences was voted by its industry peers as having the most promising pipeline in the biotechnology industry. CAR peptide has demonstrated selective penetration of co-administered therapeutics in PAH, decreased time duration of wound healing and reduces scarring. Recent discoveries have indicated CAR’s potential to ameliorate cancer cachexia and to provide a more effective therapy for sepsis survival.

pipeline graph copy 2

Next Steps: